HER-2/neu amplification predicts poor survival in node-positive breast cancer

HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages. Amplification (2- greater than 30 copies) was found in 17% of these tumors and high expression was seen...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1990-07, Vol.50 (14), p.4332-4337
Main Authors: BORG, A, TANDON, A. K, SIGURDSSON, H, CLARK, G. M, FERNO, M, FUQUA, S. A. W, KILLANDER, D, MCGUIRE, W. L
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Biological and medical sciences
Biomarkers, Tumor - analysis
Blotting, Western
breast
Breast Neoplasms - analysis
Breast Neoplasms - genetics
Breast Neoplasms - pathology
carcinoma
Female
Gene Amplification
Gene Expression
Gynecology. Andrology. Obstetrics
Humans
Immune Sera
Lymphatic Metastasis
Mammary gland diseases
Medical sciences
Menopause
Molecular Sequence Data
Peptides - chemical synthesis
Peptides - immunology
Prognosis
Protein-Tyrosine Kinases - genetics
Proto-Oncogene Proteins - analysis
Proto-Oncogene Proteins - genetics
Proto-Oncogenes
Receptor, ErbB-2
Receptors, Estrogen - analysis
Receptors, Progesterone
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages. Amplification (2- greater than 30 copies) was found in 17% of these tumors and high expression was seen in 19%. There was a striking coincidence between gene amplification and high expression. Tumors associated with many involved axillary lymph nodes or with Stage IV disease were more often HER-2/neu amplified or overexpressed. Furthermore, gene alteration was strongly correlated with the absence of steroid receptors and with larger tumor size. High expression without gene amplification was seen in a minor subset of tumors of less aggressive character. Neither amplification nor overexpression was correlated with disease outcome for patients with negative axillary lymph nodes. For node-positive patients, however, HER-2/neu amplification was a significant predictor of early relapse and death (median follow-up = 45 months), and a similar trend, although not significant, existed for high gene expression. Multivariate analyses indicated that HER-2/neu alterations were not independent predictors of patient outcome.
ISSN:0008-5472
1538-7445